Assessment of serum enzymatic markers of cardiomyocytes injury in female dogs submitted to ketamine S(+), atropin and xylazine association.
OBJECTIVE
To assessment of the aspartate aminotransferase (AST), creatine kinase (CK) and creatine kinase isoenzyme fraction MB (CK-MB) serum activity in female dogs anesthetized with ketamine S (+), atropine and xylazine in several associations.


METHODS
Twenty three healthy female dogs randomly distributed in four groups named as GI (n=6), GII (n=6), GIII (n=6) and GIV (n=5) were treated respectively with atropine and ketamine S(+) (0.04 mg/kg; 10 mg/kg); ketamine S(+) (10 mg/kg); atropine, xylazine and ketamine S(+) (0.04 mg/kg; 1.1 mg/kg; 10 mg/kg) and xylazine and ketamine S(+) (1.1 mg/kg; 10 mg/kg). AST, CK and CK-MB serum activity measurement before pre-medication (M0) and one, two, three, six, 12, 24, 36 hours after.


RESULTS
There was no significant change in AST, CK e CK-MB serum activity among groups. However, CK serum activity in relation to moments within the groups was increased in all groups over the time in spite of treatment, except GI. In relation to CK-MB activity, in the moments within the group, it was observed an increase compared to baseline in all groups.


CONCLUSIONS
Creatine kinase and creatine kinase fraction MB isoenzyme showed changes in their mean values remained higher than baseline for a longer time in GIII and GIV.
Franco
Leandro Guimarães
LG
Animal Science Post-Graduation Program, Veterinary College, Federal University of Goias, Goias, Brazil. lgvarjao@yahoo.com.br
Fioravanti
Maria Clorinda Soares
MC
Damasceno
Adilson Donizeti
AD
Borges
Aline Cardoso
AC
Soares
Lorena Karine
LK
Rabelo
Rogério Elias
RE
Silva
Luiz Antônio Franco da
LA
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000778:Anesthetics, Dissociative / Q000494:pharmacology*; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000201:enzymology*; D003402:Creatine Kinase / Q000097:blood*; D052279:Creatine Kinase, MB Form / Q000097:blood; D004195:Disease Models, Animal; D004285:Dogs; D005260:Female; D007649:Ketamine / Q000494:pharmacology; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000201:enzymology; D011897:Random Allocation; D014991:Xylazine / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D000778:Anesthetics, Dissociative; D015415:Biomarkers; D014991:Xylazine; D007649:Ketamine; D001219:Aspartate Aminotransferases; D003402:Creatine Kinase; D052279:Creatine Kinase, MB Form